Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - MADRIGAL PHARMACEUTICALS, INC. | a12-15567_1ex99d1.htm |
| EX-99.2 - EX-99.2 - MADRIGAL PHARMACEUTICALS, INC. | a12-15567_1ex99d2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 27, 2012
SYNTA PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-33277 |
|
04-3508648 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
45 Hartwell Avenue
Lexington, MA 02421
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (781) 274-8200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure.
On June 27, 2012, Synta Pharmaceuticals Corp. (“Synta”) announced results from a planned interim analysis of the GALAXY trial, a randomized Phase 2b/3 study designed to evaluate the efficacy and safety of Synta’s lead Hsp90 inhibitor, ganetespib, in combination with standard-of-care docetaxel vs. docetaxel alone as second-line treatment for advanced non-small cell lung cancer, and held a conference call to present the results. A copy of the presentation used on the conference call is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such Section 18, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
ITEM 8.01 Other Events.
On June 27, 2012, Synta issued a press release announcing results from the planned interim analysis of the GALAXY trial described above. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
|
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
GALAXY Trial Interim Results Presentation, dated June 27, 2012 |
|
|
|
|
|
99.2 |
|
Press Release, dated June 27, 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
SYNTA PHARMACEUTICALS CORP. |
|
|
|
|
|
|
|
|
|
|
Dated: June 28, 2012 |
/s/ Keith S. Ehrlich |
|
|
Keith S. Ehrlich |
|
|
Vice President, Finance and Administration |
|
|
Chief Financial Officer |